Table 2.
Proportion and risk of CKD progression in patients with CKD stage 1–5, according to stain use.
| No. of events | No. of patients | Proportion (%) | Unadjusted odds ratio | Adjusted odds ratiob | |
|---|---|---|---|---|---|
| Total | |||||
| Statin Users | 237 | 825 | 28.73 | 0.93 (0.78, 1.10) | 0.80 (0.63, 1.01) |
| Statin Nonusers | 793 | 2616 | 30.31 | 1.00 | 1.00 |
| Stage 1–3a | |||||
| Statin Users | 121 | 423 | 28.61 | 1.08 (0.85, 1.38) | 0.97 (0.68, 1.39) |
| Statin Nonusers | 350 | 1294 | 27.05 | 1.00 | 1.00 |
| Stage 3b-5 | |||||
| Statin Users | 116 | 402 | 28.86 | 0.81 (0.63, 1.03) | 0.68 a (0.48, 0.95) |
| Statin Nonusers | 443 | 1322 | 33.51 | 1.00 | 1.00 |
Note: Values in parentheses are 95% confidence interval.
aP < 0.001.
bAdjustments were made for age, sex, diabetes mellitus, coronary artery disease, stroke, cancer, Charlson comorbidity index, Statin drug used within 1 year before the index date, body mass index, smoking, alcohol, betel nut, urine protein and creatinine ratio, and baseline estimated glomerular filtration rate.